EYE ON CHINA.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      CHINA Biologic Products Inc.; BAYER HealthCare AG
    • Abstract:
      China Biologic receives GMP certification at its Guizhou Taibang facility. Hua Medicine's novel glucokinase activator reports positive Phase 1a data for diabetes and initiates Phase 1b trials. QIAGEN launches QuantiFERON-TB gold in-tube in China to aid tuberculosis control. AirWare Labs expands manufacturing and sales into China. Global Partners SillaJen, Transgene and Lee's Pharmaceutical confirm clinical development plan for Pexa-Vec. Gyros and Tekon Biotech sign distribution agreement. AstraZeneca and Shenzhen University Health Science Center to collaborate on chronic kidney disease. Bayer Healthcare to significantly increase production capacity in China. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Asia Pacific Biotech News is the property of World Scientific Publishing Company and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)